Psychopharmacology

, Volume 178, Issue 4, pp 514–523

Ziprasidone and haloperidol in the treatment of acute exacerbation of schizophrenia and schizoaffective disorder: comparison of intramuscular and oral formulations in a 6-week, randomized, blinded-assessment study

  • Shlomo Brook
  • Jeorg Walden
  • Isma Benattia
  • Cynthia O. Siu
  • Steven J. Romano
Original Investigation

DOI: 10.1007/s00213-004-2082-5

Cite this article as:
Brook, S., Walden, J., Benattia, I. et al. Psychopharmacology (2005) 178: 514. doi:10.1007/s00213-004-2082-5

Abstract

Rationale

Conventional intramuscular (IM) antipsychotics used in managing acute exacerbation of schizophrenia are associated with side effects such as acute dystonia.

Objectives

To compare the efficacy and tolerability of sequential IM/oral ziprasidone with haloperidol in acute exacerbation of schizophrenia or schizoaffective disorder.

Methods

In a 6-week, multicenter, parallel-group, flexibly dosed study, patients were randomized to ziprasidone (IM up to 3 days, then oral 40–80 mg, b.i.d.) or haloperidol (IM up to 3 days, then oral 5–20 mg/day). Assessments were rater-blinded.

Results

At the end of IM treatment, patients receiving ziprasidone (n=427) showed significantly improved Brief Psychiatric Rating Scale Total (BPRS total) scores compared with those receiving haloperidol (n=138) [least-squares (LS) mean change −6.14 for ziprasidone versus −4.13 for haloperidol, P<0.0018]. At endpoint, there were no significant between-group differences in BPRS total scores. There was a significantly greater improvement in BPRS negative subscale scores in ziprasidone-treated patients, both at the end of IM treatment (LS mean change −1.15 for ziprasidone and −0.28 for haloperidol, P<0.0001) and at study endpoint (LS mean change −2.94 for ziprasidone and −2.24 for haloperidol, P<0.0001). Haloperidol-treated patients exhibited significantly greater increases in Extrapyramidal Symptom Rating Scale at end of IM treatment and at endpoint (P<0.0001). They also had significantly higher ratings on the Barnes Akathisia Scale (P<0.0001) and the Movement Disorder Burden Score (P<0.005), as well as higher incidences of movement disorder-related adverse events.

Conclusions

Sequential IM and oral ziprasidone offers important efficacy and tolerability advantages over haloperidol in acute schizophrenia.

Keywords

Acute schizophreniaAntipsychoticsHaloperidolSchizophreniaSequential intramuscular/oralZiprasidone

Copyright information

© Springer-Verlag 2005

Authors and Affiliations

  • Shlomo Brook
    • 1
  • Jeorg Walden
    • 2
  • Isma Benattia
    • 3
  • Cynthia O. Siu
    • 3
  • Steven J. Romano
    • 3
  1. 1.Department of PsychiatrySterkfontein HospitalKrugersdorpSouth Africa
  2. 2.Universitätsklinik für Psychiatrie und PsychosomatikFreiburgGermany
  3. 3.Pfizer IncNew YorkUSA